SCHEMBL1958105

SCHEMBL1958105

CN1CCN(Nc2ccc(S(=O)(=O)NC(=O)c3ccccc3Oc3cccc(F)c3F)cc2[N+](=O)[O-])CC1

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 15/20 0.59
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2776802 0.88 BCL2 (0.61) BCL2
SCHEMBL1959691 0.85 BCL2 (0.51) BCL2
SCHEMBL1956705 0.85 BCL2 (0.61) BCL2
SCHEMBL2730313 0.80 BCL2 (0.60) BCL2
SCHEMBL2725866 0.79 BCL2 (0.61) BCL2
SCHEMBL29657285 0.79 BCL2 (0.61) BCL2
SCHEMBL2507851 0.73 BCL2 (0.54) BCL2
SCHEMBL2775444 0.73 BCL2 (0.60) BCL2
SCHEMBL1958805 0.73 BCL2 (0.62) BCL2
SCHEMBL29657389 0.71 BCL2 (0.61) BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507211-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 — — EP claimed
WO-2011068560-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-06-09 — — WO claimed
WO-2010065824-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 — — WO claimed
WO-2010065824-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 — — WO disclosed
Send feedback